NCT03206788

Losartan and Inflammation in Cystic Fibrosis

Losartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) Recovery

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: University of Miami · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to examine if a specific drug called losartan (Cozaar ®), generally used to treat high blood pressure and to protect kidneys from damage in patients suffering from Diabetes Mellitus, will have any effect on the nasal inflammation in patients with cystic fibrosis (CF). The study will be performed at the Pulmonary Division at the University of Miami, Cincinnati Children's Medical Hospital Center, University of Kansas Medical Center and University of Alabama-Birmingham.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	Losartan	25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
DRUG	placebo	Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.

Timeline

• Start date: 2017-11-11
• Primary completion: 2019-10-24
• Completion: 2019-12-30
• First posted: 2017-07-02
• Last updated: 2020-11-27
• Results posted: 2020-11-13

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study